In a frothy market, it's more important than ever to stay focused on profitable leaders with a dominant market position.

Investing in startups has always been a mixture of art and science—a delicate balance of data-driven analysis and qualitative judgment. This is especially true for the gaming industry, which is my ...

Sustainable investing doesn’t work. ESG is just marketing. Impact investing is a club. We’ve heard it all, and after decades assessing and carefully considering the underlying issues, we firmly ...

Shorter-term US Treasury yields have fallen, while yields on longer-dated bonds could remain elevated, thanks to the threat of higher inflation and investor concerns surrounding the federal deficit.

In startup fundraising, ownership structure can be as decisive as revenue growth or market size. Investors often review a company’s capitalization table, a record of who owns what, before committing ...

Banks' credit losses are starting to spook the stock market. Struggling to find their way amid an ongoing economic-data blackout and renewed trade-war tensions between the U.S. and China, investors ...

A yield this high grabs attention—but is it too good to be true? I look at the pros and cons of investing in BITO. Here’s what every income investor should consider before buying in. However, my view ...

The episode features three entrepreneurs delivering pitches to a panel of top investors, who offer real-world lessons on what ...

Gold investors are experiencing some serious whiplash right now. Earlier this week, prices crashed from the latest record-high of above $4,300 per ounce, dipping all the way down to about $4,000 per ...

A push for greater opacity in America’s capital markets is gathering steam. President Trump has advocated for ending the federal requirement that public companies report financial results quarterly.

Talk surrounding the price of gold is ubiquitous. And that was certainly the case this week after the precious metal surged past yet another price record, this time breaking the $4,000 per ounce mark.

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...